Highland Capital Management LP Holding in Calpine (CPN) Has Lowered by $394,590 as Share Price Rose; Carlson Capital Management Boosted Its Lilly Eli Co (LLY) Stake by $331,415 as Share Value Declined

February 21, 2018 - By Darrin Black

Carlson Capital Management increased its stake in Lilly Eli Co (LLY) by 138.75% based on its latest 2017Q3 regulatory filing with the SEC. Carlson Capital Management bought 3,899 shares as the company’s stock declined 3.22% while stock markets rallied. The institutional investor held 6,709 shares of the major pharmaceuticals company at the end of 2017Q3, valued at $574,000, up from 2,810 at the end of the previous reported quarter. Carlson Capital Management who had been investing in Lilly Eli Co for a number of months, seems to be bullish on the $82.32 billion market cap company. The stock increased 1.37% or $1.06 during the last trading session, reaching $78.61. About 2.03M shares traded. Eli Lilly and Company (NYSE:LLY) has risen 4.70% since February 21, 2017 and is uptrending. It has underperformed by 12.00% the S&P500.

James Dondero decreased its stake in Calpine Corp (CPN) by 32.73% based on its latest 2017Q3 regulatory filing with the SEC. Highland Capital Management Lp sold 28,185 shares as the company’s stock rose 19.88% with the market. The hedge fund run by James Dondero held 57,940 shares of the central company at the end of 2017Q3, valued at $855,000, down from 86,125 at the end of the previous reported quarter. Highland Capital Management Lp who had been investing in Calpine Corp for a number of months, seems to be less bullish one the $5.47B market cap company. The stock decreased 0.07% or $0.01 during the last trading session, reaching $15.16. About 3.82M shares traded. Calpine Corporation (NYSE:CPN) has declined 5.37% since February 21, 2017 and is downtrending. It has underperformed by 22.07% the S&P500.

Among 20 analysts covering Eli Lilly and Company (NYSE:LLY), 11 have Buy rating, 2 Sell and 7 Hold. Therefore 55% are positive. Eli Lilly and Company had 95 analyst reports since July 23, 2015 according to SRatingsIntel. As per Monday, June 5, the company rating was maintained by BMO Capital Markets. The rating was maintained by Piper Jaffray with “Buy” on Thursday, October 12. The company was upgraded on Friday, December 16 by Morgan Stanley. As per Thursday, November 16, the company rating was maintained by Jefferies. The rating was maintained by Leerink Swann on Tuesday, October 13 with “Outperform”. Jefferies maintained Eli Lilly and Company (NYSE:LLY) on Tuesday, April 11 with “Buy” rating. On Thursday, August 31 the stock rating was maintained by Piper Jaffray with “Buy”. Jefferies maintained Eli Lilly and Company (NYSE:LLY) rating on Tuesday, January 16. Jefferies has “Buy” rating and $100.0 target. The firm earned “Underperform” rating on Thursday, February 1 by BMO Capital Markets. The firm earned “Buy” rating on Friday, April 7 by Citigroup.

Investors sentiment decreased to 0.89 in Q3 2017. Its down 0.01, from 0.9 in 2017Q2. It dived, as 66 investors sold LLY shares while 386 reduced holdings. 79 funds opened positions while 325 raised stakes. 827.83 million shares or 0.59% more from 823.00 million shares in 2017Q2 were reported. Pinebridge Investments Ltd Partnership holds 131,544 shares or 0.27% of its portfolio. Atlantic Tru Group Ltd Llc holds 0.08% of its portfolio in Eli Lilly and Company (NYSE:LLY) for 215,251 shares. Bryn Mawr Trust owns 44,435 shares. Horan Capital Advsrs Llc accumulated 310 shares. Sentinel Asset Mngmt Incorporated holds 271,500 shares. Shelton Capital Mngmt owns 10,041 shares or 0.07% of their US portfolio. Ipswich Inv Management holds 8,280 shares or 0.32% of its portfolio. Columbia Asset Mgmt holds 0.13% or 5,070 shares. Nj State Employees Deferred Compensation Plan has invested 0.54% in Eli Lilly and Company (NYSE:LLY). Veritable LP has invested 0.1% of its portfolio in Eli Lilly and Company (NYSE:LLY). Private Advisors invested 11.34% of its portfolio in Eli Lilly and Company (NYSE:LLY). Moreover, Inv House Ltd Liability Com has 0.38% invested in Eli Lilly and Company (NYSE:LLY) for 33,627 shares. 30,693 were accumulated by Bb&T. 400 were accumulated by Live Your Vision Limited Co. Hyman Charles D holds 0.06% of its portfolio in Eli Lilly and Company (NYSE:LLY) for 5,300 shares.

Since August 31, 2017, it had 0 insider buys, and 8 sales for $84.24 million activity. 900 shares were sold by Zakrowski Donald A, worth $72,981 on Monday, February 5. Simmons Jeffrey N sold $1.08M worth of Eli Lilly and Company (NYSE:LLY) on Monday, December 11.

Carlson Capital Management, which manages about $1.18 billion and $340.82 million US Long portfolio, decreased its stake in Vanguard Intl Equity Index F (VWO) by 8,970 shares to 148,696 shares, valued at $6.48M in 2017Q3, according to the filing. It also reduced its holding in Spdr S&P 500 Etf Tr (SPY) by 1,198 shares in the quarter, leaving it with 5,946 shares, and cut its stake in Apple Inc (NASDAQ:AAPL).

Since August 23, 2017, it had 0 insider buys, and 2 selling transactions for $3.26 million activity. $577,624 worth of Calpine Corporation (NYSE:CPN) was sold by Hill Thad on Tuesday, December 12. The insider MILLER W. THADDEUS sold $2.69M.

Highland Capital Management Lp, which manages about $15.04B and $2.27B US Long portfolio, upped its stake in Grupo Supervielle S A by 111,385 shares to 461,135 shares, valued at $11.39M in 2017Q3, according to the filing. It also increased its holding in Citigroup Inc (Call) (NYSE:C) by 195,000 shares in the quarter, for a total of 1.17 million shares, and has risen its stake in Molina Healthcare Inc (NYSE:MOH).

Analysts await Calpine Corporation (NYSE:CPN) to report earnings on February, 23. They expect $0.13 EPS, up 132.50% or $0.53 from last year’s $-0.4 per share. CPN’s profit will be $46.87 million for 29.15 P/E if the $0.13 EPS becomes a reality. After $0.63 actual EPS reported by Calpine Corporation for the previous quarter, Wall Street now forecasts -79.37% negative EPS growth.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>